Jiang Wu is currently the Associate Vice President of Analytical Development at Eli Lilly and Company, where they focus on analytical development and control strategy for cell therapy products. Previously, Wu served as the VP and Head of Bioanalytical and CMC Analytical Development at Sigilon Therapeutics from 2021 to 2024, leading teams in bioanalytical and biomarker development. With a rich background in the biopharmaceutical industry, they have held various senior positions at notable companies including AbbVie, Takeda, and Pfizer, contributing significantly to drug characterization and biomarker validation. Wu earned a Ph.D. in Analytical Biochemistry from Michigan State University in 1997.
This person is not in the org chart
This person is not in any teams
This person is not in any offices